What is the generic name for Thymoglobulin?

What is the generic name for Thymoglobulin?

Use Thymoglobulin (antithymocyte globulin (rabbit)) as ordered by your doctor.

How long does Thymoglobulin last?

2.1 Dosing Information The usual duration of administration is 4 to 7 days. The recommended dosage of THYMOGLOBULIN for treatment of acute rejection in patients receiving a kidney transplant is 1.5 mg/kg of body weight administered daily for 7 to 14 days.

When is Thymoglobulin given?

Thymoglobulin was administered daily between day 0 and day 7 at a dose of 1.25 mg/kg/day and five injections of daclizumab were administered at a dose of 1 mg/kg on days 0, 14, 28, 42 and 56.

Can Thymoglobulin be given peripherally?

The recommended route of administration for Thymoglobulin is intravenous infusion using a high flow vein; however, it may be administered through a peripheral vein.

What’s the difference between Atgam and Thymoglobulin?

The difference is that ATGAM is derived from horse plasma, while Thymoglobulin is derived from rabbit plasma. Thymoglobulin’s past positive results with resistant or relapsed patients suggested that it might be a better choice as a patient’s first aplastic anemia treatment.

Which is the most common side effect of thymoglobulin?

Infections occurring in ≥ 5% of the patients in either treatment group during the 12-month follow-up are summarized in Table 2. Urinary tract infection was the most frequent type of infection, and was reported as severe in 9% of THYMOGLOBULIN-treated patients and in 2% of Active Comparator-treated patients.

Are there any immunosuppressive agents similar to Atgam?

Thymoglobulin (SangStat Medical Corporation, Menlo Park, CA) is a polyclonal immunosuppressive agent similar to Atgam but is produced in the rabbit. Like Atgam, Thymoglobulin contains antibodies to a wide variety of T-cell antigens and MHC antigens (15, 16).

Which is better for chronic rejection Atgam or Thymoglobulin?

Both Atgam and Thymoglobulin have been shown to reverse acute rejection and thus reduce the risks of developing chronic rejection (17-20). However, a recent randomized double-blinded multicenter trial indicated that Thymoglobulin was more efficacious than Atgam to treat rejection (20).